QBL ANNOUNCEMENT; close to SIGN DEALS and new PARTNERSHIPS.
QBL ANNOUNCEMENT; close to SIGN DEALS and new PARTNERSHIPS.
Sydney, April 26, 2018 AEST (ABN Newswire) - Members of the Queensland Bauxite (ASX:QBL) (or "the Company" management team responsible for the development of the South Johnstone Bauxite Project, headed by QBL's Chief Geoscientist Dr Robert Coenraads PhD, as part of its ongoing marketing strategy, and as part of the operational plan under the existing granted Mineral Development Licence on South Johnstone, are currently visiting several Chinese bauxite refineries and aluminium smelters whose executives have expressed interest in partnering in the development of our South Johnstone Bauxite Project.
The QBL team is also meeting with Hong Kong based metals marketing platforms who have offered to assist in the commodity trading with QBL.
The timing of this visit is opportune as aluminium prices are forecast to grow strongly in 2018 and 2019, according to the Aluminium, alumina and bauxite, Resources and Energy Quarterly, December 2017 published by the Office of the Chief Economist of the Australian Government Department of Industry Innovation and Science.
The Company will update the market with details once commercial arrangements are finalised with any of the relevant business organisations.
The Company continues to work towards finalising the application for a Mining Lease (ML) at South Johnstone, with its environmental team, Northern Resource Consultants, monitoring on-site surface water and groundwater quality, and background dust and noise levels, in preparation for the ML application which is now almost complete.
Comment from Pnina Feldman, Chairperson of QBL
"We are excited to finally see the light at the end of the tunnel for this project, with potential business arrangements which we believe will turn our South Johnstone Bauxite deposit into the lucrative project that we have always anticipated it could become. The Company's current trip to China should further these potential arrangements and partnerships that should establish South Johnstone as an exciting project that will benefit the Company and all shareholders."
https://www.queenslandbauxite.com/
Here you have the possibility to take advantage on facts and info from QBL.Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up.Contact information to the QBL Investor service, who can reply on questions, serviceminded.
Robert
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...
Continue Reading
AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...
Continue Reading
They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...
Continue Reading
Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...
Continue Reading
Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...
Continue Reading
Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...
Continue Reading
Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...
Continue Reading
Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...
Continue Reading
Top 5 Most Recently Viewed Articles
LenioBio and ReciBioPharm Team Up for Vaccine Tech Advancement LenioBio, known for its innovative approaches to rapid protein expression, has announced an exciting collaboration with ReciBioPharm, aiming to boost vaccine production and efficiency through advanced technology. This partnership is set to play a vital role in enhancing the capabilities of protein...
Continue Reading
Trump and Cuban's Feud Intensifies Donald Trump recently directed a fierce critique at billionaire Mark Cuban, accusing him of being a "loser" and labeling him as a "weak and pathetic bully." This latest insult arises from a public dispute ignited by Cuban's criticisms regarding Trump's proposed tariff strategies. The Catalyst of the Conflict The discord took a public...
Continue Reading
Cascale Unveils New Membership Engagement Model Cascale, known previously as the Sustainable Apparel Coalition, is implementing a revolutionary member engagement and governance model aimed at ensuring comprehensive participation across its platform. This initiative emphasizes the vital role of suppliers and manufacturers, thereby enhancing decision-making processes within...
Continue Reading
Cosmic Crisp® Collaborates with Dunford® for New Dessert Launch Cosmic Crisp® is making waves in the dessert market with an exciting collaboration with Dunford®, a brand celebrated for its exquisite pastries. Let’s explore this innovative partnership that introduces unique experiences for dessert lovers. The Launch of a New Pastry Delight The partnership between...
Continue Reading
Silexion Therapeutics Engages Investors with Public Offering Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotech company focused on developing groundbreaking RNA interference (RNAi) therapies aimed at treating KRAS-driven cancers. Recently, the company announced closing a public offering priced at $1.35 per share, allowing investors to acquire a total of...
Continue Reading